Business
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)
LAKE ZURICH, Ill., October 29, 2025--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the U.S. Food and Drug Administration (FDA) designated Conexxence®(1) and Bomyntra®(2) (denosumab-bnht) as interchangeable biosimilars to the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively.
About this update from Fresenius Se & Co. Kgaa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":593,"url":"https://media.zenfs.com/en/business-wire.com/1602916550df060a62f4bd8d3d49d910"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o5lG7pwmneLKRpWxSZs4AQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1602916550df060a62f4bd8d3d49d910","width":960,"height":285},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/nZqzzJdxUWLESgT5luhiFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1602916550df060a62f4bd8d3d49d910","width":1200,"height":356}},"lazy":false},{"type":"text","content":"LAKE ZURICH, Ill., October 29, 2025--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the U.S. Food and Drug Administration (FDA) designated Conexxence®(1) and Bomyntra®(2) (denosumab-bnht) as interchangeable biosimilars to the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively.","length":437,"tagName":"p"},{"type":"text","content":""Fresenius Kabi is pleased to receive this interchangeable designation for Conexxence and Bomyntra to create access for patients and healthcare professionals to important, high-quality therapies at a reduced cost," said Dr. Sang-Jin Pak, President Biopharma and member of the Fresenius Kabi Management Board.","length":318,"tagName":"p"},{"type":"text","content":"About Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht)","length":65,"tagName":"p"},{"type":"text","content":"Conexxence® (denosumab-bnht) is approved for use in various adult patient populations at high risk for fractures, including individuals with osteoporosis, patients undergoing certain cancer treatments that affect bone density, and patients receiving long-term glucocorticoid therapy. In the U.S., Conexxence® carries a boxed warning and includes a Risk Evaluation and Mitigation Strategy (REMS) program, which aims to educate prescribers and patients about the risk of severe hypocalcemia in patients with advanced chronic kidney disease, including those on dialysis. Conexxence® is contraindicated in patients with hypocalcemia, during pr...